2375 Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)

H Ueno,M Nagase,Y Hamamoto,S Egawa,S Ohkawa

doi:10.1016/s0959-8049(16)31291-6

2375 Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)

H Ueno, M Nagase + Show 3 more

https://doi.org/10.1016/s0959-8049(16)31291-6

Copy DOI

Export

Save

Cite

Journal: European Journal of Cancer

Publication Date: Sep 1, 2015

#GEST Study #Advanced Pancreatic Cancer #Advanced Cancer #Study Of Gemcitabine #Pancreatic Cancer #Prognostic Index

Abstract
Full-Text
Similar Papers

Abstract

Listen

2375 Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: European Journal of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

2375 Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)